Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
Hasegawa K, Kagabu M, Mizuno M, Oda K, Aoki D, Mabuchi S, Kamiura S, Yamaguchi S, Aoki Y, Saito T, Yunokawa M, Takehara K, Okamoto A, Ochiai K, Kimura T.
Hasegawa K, et al. Among authors: mabuchi s.
Invest New Drugs. 2017 Dec;35(6):800-812. doi: 10.1007/s10637-017-0504-6. Epub 2017 Sep 2.
Invest New Drugs. 2017.
PMID: 28864978
Clinical Trial.